Startup profile · funding coverage
DeepCell
AI-powered single-cell imaging platform classifying cells by morphology without markers.
Stage
See coverage
Status
private
Coverage
full
Why DeepCell is interesting
Stanford spinout using computer vision on intact cells — a16z stayed in through Koch-led Series B as morpholomics atlas scaled past 1B images.
Key facts
- Series B (Mar 2022): $73M led by Koch Disruptive Technologies; a16z re-upped (Fierce Biotech)
- Series A (Dec 2020): $20M led by Bow Capital with a16z participation (company press)
- Co-investors not in VCT directory: Koch Disruptive Technologies, Bow Capital, Bridger Healthcare, Horizons Ventures, Casdin Capital
- VCT directory co-investors: none mapped (non-directory syndicates noted above); reviewed 2026-07-24
Investors in our directory
Funds linked from DeepCell's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences AI & Machine Learning
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about DeepCell
Funding context and why this company shows up in venture coverage.
DeepCell is listed among Andreessen Horowitz (a16z) investments on a16z’s public investment list.
We track a16z-backed companies that are strategically relevant for founders and investors following AI, American Dynamism, crypto, bio, and enterprise software.
Last updated: 2026-07-24